1. Home
  2. LIXT vs SOPA Comparison

LIXT vs SOPA Comparison

Compare LIXT & SOPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • SOPA
  • Stock Information
  • Founded
  • LIXT 2005
  • SOPA 2018
  • Country
  • LIXT United States
  • SOPA Singapore
  • Employees
  • LIXT N/A
  • SOPA N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • SOPA EDP Services
  • Sector
  • LIXT Health Care
  • SOPA Technology
  • Exchange
  • LIXT Nasdaq
  • SOPA Nasdaq
  • Market Cap
  • LIXT 4.1M
  • SOPA 3.8M
  • IPO Year
  • LIXT N/A
  • SOPA 2021
  • Fundamental
  • Price
  • LIXT $1.17
  • SOPA $1.31
  • Analyst Decision
  • LIXT
  • SOPA Strong Buy
  • Analyst Count
  • LIXT 0
  • SOPA 1
  • Target Price
  • LIXT N/A
  • SOPA $15.00
  • AVG Volume (30 Days)
  • LIXT 17.8K
  • SOPA 969.0K
  • Earning Date
  • LIXT 05-12-2025
  • SOPA 05-20-2025
  • Dividend Yield
  • LIXT N/A
  • SOPA N/A
  • EPS Growth
  • LIXT N/A
  • SOPA N/A
  • EPS
  • LIXT N/A
  • SOPA N/A
  • Revenue
  • LIXT N/A
  • SOPA $6,731,955.00
  • Revenue This Year
  • LIXT N/A
  • SOPA $26.32
  • Revenue Next Year
  • LIXT N/A
  • SOPA N/A
  • P/E Ratio
  • LIXT N/A
  • SOPA N/A
  • Revenue Growth
  • LIXT N/A
  • SOPA N/A
  • 52 Week Low
  • LIXT $1.02
  • SOPA $0.64
  • 52 Week High
  • LIXT $3.50
  • SOPA $6.75
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 41.14
  • SOPA 56.21
  • Support Level
  • LIXT $1.28
  • SOPA $1.07
  • Resistance Level
  • LIXT $1.41
  • SOPA $1.67
  • Average True Range (ATR)
  • LIXT 0.12
  • SOPA 0.15
  • MACD
  • LIXT -0.01
  • SOPA 0.01
  • Stochastic Oscillator
  • LIXT 3.23
  • SOPA 40.00

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About SOPA Society Pass Incorporated

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.

Share on Social Networks: